Daffodil Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 11-01-2025
- Paid Up Capital ₹ 1.23 M
as on 11-01-2025
- Company Age 39 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 3.30 M
as on 11-01-2025
- Revenue %
(FY 2022)
- Profit -337.59%
(FY 2022)
- Ebitda 88.52%
(FY 2022)
- Net Worth -1.52%
(FY 2022)
- Total Assets -1.52%
(FY 2022)
About Daffodil Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.23 M.
The company has closed loans amounting to ₹3.30 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Jitendra Patel and Vijaykumar Patel serve as directors at the Company.
- CIN/LLPIN
U24230GJ1985PTC008138
- Company No.
008138
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Sep 1985
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Daffodil Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jitendra Patel  | Director | 27-Sep-1985 | Current |
| Vijaykumar Patel | Director | 11-Nov-2003 | Current |
Financial Performance of Daffodil Pharmaceuticals.
Daffodil Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 337.59% decrease in profit. The company's net worth dipped by a decrease of 1.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Daffodil Pharmaceuticals?
In 2022, Daffodil Pharmaceuticals had a promoter holding of 77.11% and a public holding of 22.89%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Daffodil Pharmachem Private LimitedActive 31 years 6 monthsJitendra Patel and Vijaykumar Patel are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 12 Dec 1987 | ₹1.20 M | Satisfied |
Gujarat State Financial Corporation Creation Date: 16 May 1986 | ₹2.10 M | Satisfied |
How Many Employees Work at Daffodil Pharmaceuticals?
Unlock and access historical data on people associated with Daffodil Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Daffodil Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Daffodil Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
